[Featured Stock] Nexten Bio Surges on News of US Subsidiary Rossbivo Developing 'Omicron'-Targeted Treatment
[Asia Economy Reporter Jang Hyowon] Nexten Bio is showing strong performance following news that its U.S. subsidiary Rosvivo Therapeutics is developing a treatment targeting the COVID-19 Omicron variant.
As of 9:22 AM on the 1st, Nexten Bio is trading at 7,080 KRW, up 4.58% compared to the previous day.
According to Nexten Bio, recently CEO No Seung-il of Rosvivo and the research team have discovered an anti-coronavirus microRNA (miRNA) that can target all seven confirmed COVID-19 variants. Among the targetable viruses are SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome), which are prone to developing into severe cases.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- One in 77 Koreans Exposed to Drugs... Enough Money for 6,600 Luxury Gangnam Apartments Circulates in Drug Market [ChwiYakGukga] ⑩
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
A Nexten Bio official explained, "The discovered anti-coronavirus miRNA targets the spike protein. We believe it will also be effective against the Omicron spike, and we plan to proceed with related experiments to actively develop the treatment."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
